Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors Meeting Abstract

International Collaboration

cited authors

  • Arkenau, H-T.; Guthrie, T.; Mekhail, T.; Cortinovis, D.; Antonuzzo, L.; Bruce, J. Y.; Gabrail, N.; Anderson, I.; Oh, S. C.; Oh, S. Y.; Nott, L.; Shah, M. A.; Sanborn, R. E.; Oh, D-Y.; Cho, J. Y.; Lin, C-C.; Lee, A.; Wang, Y.; Wang, Z.; Sher, A.

authors

Publication Date

  • January 1, 2021

webpage

published in

category

start page

  • S671

end page

  • S672

volume

  • 32